Stock comparison
Abbott Laboratories
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ABT
Abbott Laboratories
Market cap
$152.25B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ABT | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 61C | 65C | GMAB |
| Benjamin Graham | 69B | 64C | ABT |
| Philip Fisher | 46D | 48D | GMAB |
| Peter Lynch | 24F | 25F | GMAB |
| Joel Greenblatt | 42D | 76B | GMAB |
| Charlie Munger | 57C | 68C | GMAB |
| Terry Smith | 54D | 71C | GMAB |
Side-by-side metrics
| Metric | ABT | GMAB |
|---|---|---|
| Market cap | $152.25B | $16.5B |
| P/E (TTM) | 23.5x | 6.2x |
| EV/EBIT | 21.7x | 12.0x |
| ROIC (TTM) | 6.56% | 43.78% |
| Gross margin | 56.38% | 93.88% |
| Net margin | 13.91% | 18.23% |
| Revenue CAGR 5y | 0.72% | -18.45% |
| EPS CAGR 5y | -1.48% | -23.48% |
| Debt / Equity | 0.7x | 0.1x |
| Dividend yield | 2.89% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ABT leads on
- Revenue CAGR 5y0.72%vs -18.45%+104%
- Dividend yield2.89%vs 0.0%+100%
- EPS CAGR 5y-1.48%vs -23.48%+94%
- Market cap$152.25Bvs $16.5B+89%
GMAB leads on
- Debt / Equity0.1xvs 0.7x+89%
- ROIC (TTM)43.78%vs 6.56%+85%
- P/E (TTM)6.2xvs 23.5x+74%
- EV/EBIT12.0xvs 21.7x+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.